Seminars in Oncology
Volume 32, Issue 1 , Pages 69-75 , February 2005

Cyclooxygenase-2 inhibition in colorectal cancer: Boom or bust?

  • Rachel Sanborn

      Affiliations

    • Department of Medicine, Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR.
    • ,
  • Charles D. Blanke

      Affiliations

    • Department of Medicine, Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR.
    • Corresponding Author InformationAddress reprint requests to Charles D. Blanke, MD, FACP, Department of Medicine, Division of Hematology and Medical Oncology, Oregon Health and Science University, 3181 SW Sam Jackson Park Rd, Mail Code L586, Portland OR 97201-3098.

References 

  1. Jemal A , Tiwari RC , Murray T , et al.   Cancer statistics, 2004 . CA Cancer J Clin . 2004;54:8–29
  2. Tournigand C , Andre T , Achille E , et al.   FOLFIRI followed by FOLFOX6 or the reverse sequence in colorectal cancer (A randomized GERCOR study) . J Clin Oncol . 2004;22:229–237
  3. Willoughby DA , Moore AR , Colville-Nash PR . COX-1, COX-2, and COX-3 and the future treatment of chronic inflammatory disease . Lancet . 2000;355:646–648
  4. Harris RC , McKanna JA , Akai Y , et al.   Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction . J Clin Invest . 1994;94:2504–2510
  5. Maihöfner C , Tegeder I , Euchenhofer C , et al.   Localization and regulation of cyclo-oxygenase-1 and -2 and neuronal nitric oxide synthase in mouse spinal cord . Neuroscience . 2000;101:1093–1108
  6. Maihöfner C , Schlötzer-Schrehardt U , Gühring H , et al.   Expression of cyclooxygenase-1 and -2 in normal and glaucomatous human eyes . Invest Ophthalmol Vis Sci . 2001;42:2616–2624
  7. Eberhart CE , Coffey RJ , Radhika A , et al.   Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas . Gastroenterology . 1994;107:1183–1188
  8. Kargman SL , O’Neill GP , Vickers PJ , et al.   Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer . Cancer Res . 1995;55:2556–2559
  9. DuBois RN , Radhika A , Reddy BS , et al.   Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors . Gastroenterology . 1996;110:1259–1262
  10. Maihöfner C , Charalambous MP , Bhambra U , et al.   Expression of cyclooxygenase-2 parallels expression of interleukin-1beta, interleukin-6 and NF-kappaB in human colorectal cancer . Carcinogenesis . 2003;24:665–671
  11. Vane JR . Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs . Nature New Biol . 1971;231:232–235
  12. Simmons DL , Levy DB , Yannoni Y , et al.   Identification of a phorbol ester-repressible v-src-inducible gene . Proc Natl Acad Sci U S A . 1989;86:1178–1182
  13. Xie W , Chipman JG , Robertson DL , et al.   Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing . Proc Natl Acad Sci U S A . 1991;88:2692–2696
  14. Kujubu DA , Fletcher BS , Varnum BC , et al.   TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue . J Biol Chem . 1991;266:12866–12872
  15. O’Banion MK , Sadowski HB , Winn V , et al.   A serum- and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein . J Biol Chem . 1991;266:23261–23267
  16. Elder DJ , Baker JA , Banu NA , et al.   Human colorectal adenomas demonstrate a size-dependent increase in epithelial cyclooxygenase-2 expression . J Pathol . 2002;198:428–434
  17. Einspahr JG , Krouse RS , Yochim JM , et al.   Association between Cyclooxygenase expression and colorectal adenoma characteristics . Cancer Res . 2003;63:3891–3893
  18. Yamauchi T , Watanabe M , Kubota T , et al.   Cyclooxygenase-2 expression as a new marker for patients with colorectal cancer . Dis Colon Rectum . 2002;45:98–103
  19. Wendum D , Svrcek M , Rigau V , et al.   COX-2, inflammatory secreted PLA2, and cytoplasmic PLA2 protein expression in small bowel adenocarcinomas compared with colorectal adenocarcinomas . Mod Pathol . 2003;16:130–136
  20. Chapple KS , Scott N , Guillou PJ , et al.   Interstitial cell cyclooxygenase-2 expression is associated with increased angiogenesis in human sporadic colorectal adenomas . J Pathol . 2002;198:435–441
  21. Zhang H , Sun XF . Overexpression of cyclooxygenase-2 correlates with advanced stages of colorectal cancer . Am J Gastroenterol . 2002;97:1037–1041
  22. Chen WS , Wei SJ , Liu JM . Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodolac . Int J Cancer . 2001;91:894–899
  23. Tomozawa S , Tsuno NH , Sunami E , et al.   Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer . Br J Cancer . 2000;83:324–328
  24. Dimberg J , Samuelsson A , Hugander A , et al.   Differential expression of cyclooxygenase 2 in human colorectal cancer . Gut . 1999;45:730–732
  25. DuBois RN , Awad J , Morrow J , et al.   Regulation of eicosanoid production and mitogenesis in rat intestinal epithelial cells by transforming growth factor-α and phorbol ester . J Clin Invest . 1994;93:493–498
  26. Buchanan FG , Wang D , Bargiacchi F , et al.   Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor . J Biol Chem . 2003;278:35451–35457
  27. Inaba T , Sano H , Kawahito Y , et al.   Induction of cyclooxygenase-2 in monocyte/macrophage by mucins secreted from colon cancer cells . Proc Natl Acad Sci U S A . 2003;100:2736–2741
  28. Sonoshita M , Takaku K , Oshima M , et al.   Cyclooxygenase-2 expression in fibroblasts and endothelial cells of intestinal polyps . Cancer Res . 2002;62:6846–6849
  29. Ko SCW , Chapple KS , Hawcroft G , et al.   Paracrine cyclooxygenase-2-mediated signaling by macrophages promotes tumorigenic progression of intestinal epithelial cells . Oncogene . 2002;21:7175–7186
  30. Sun Y , Tang XM , Half E , et al.   Cyclooxygenase-2 overexpression reduces apoptotic susceptibility by inhibiting the cytochrome c-dependent apoptotic pathway in human colon cancer cells . Cancer Res . 2002;62:6323–6328
  31. Tang X , Sun YJ , Half E , et al.   Cyclooxygenase-2 overexpression inhibits death receptor 5 expression and confers resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human colon cancer cells . Cancer Res . 2002;62:4903–4908
  32. Kralj M , Kapitanović S , Kovačević D , et al.   Effect of the nonsteroidal anti-inflammatory drug indomethacin on proliferation and apoptosis of colon carcinoma cells . J Cancer Res Clin Oncol . 2001;127:173–179
  33. Arico S , Pattingre S , Bauvy C , et al.   Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line . J Biol Chem . 2002;277:27613–27621
  34. Kishimoto Y , Yashima K , Morisawa T , et al.   Effects of cyclooxygenase-2 inhibitor NS-398 on APC and c-myc expression in rat colon carcinogenesis induced by azoxymethane . J Gastroenterol . 2002;37:186–193
  35. Majima M , Hayashi I , Muramatsu M , et al.   Cyclo-oxygenase-2 enhances basic fibroblast growth factor-induced angiogenesis through induction of vascular endothelial growth factor in rat sponge implants . Br J Pathol . 2000;130:641–649
  36. Masferrer JL , Leahy KM , Koki AT , et al.   Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors . Cancer Res . 2000;60:1306–1311
  37. Pai R , Nakamura T , Moon WS , et al.   Prostaglandins promote colon cancer cell invasion; signaling by cross-talk between two distinct growth factor receptors . FASEB J . 2003;17:1640–1647
  38. Yu H-G , Huang J-A , Yang Y-N , et al.   The effects of acetylsalicylic acid on proliferation, apoptosis, and invasion of cyclooxygenase-2 negative colon cancer cells . Eur J Clin Invest . 2002;32:838–846
  39. Nagatsuka I , Yamada N , Shimizu S , et al.   Inhibitory effect of a selective cyclooxygenase-2 inhibitor on liver metastasis of colon cancer . Int J Cancer . 2002;100:515–519
  40. Wagenaar-Miller RA , Hanley G , Shattuck-Brandt R , et al.   Cooperative effects of matrix metalloproteinase and cyclooxygenase-2 inhibition on intestinal adenoma reduction . Br J Cancer . 2003;88:1445–1452
  41. Rao CV , Indranie C , Simi B , et al.   Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor . Cancer Res . 2002;62:165–170
  42. Yao M , Kargman S , Lam EC , et al.   Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice . Cancer Res . 2003;63:586–592
  43. Trifan OC , Durham WF , Salazar VS , et al.   Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11 . Cancer Res . 2002;62:5778–5784
  44. Ricchi P , Di Mattola T , Ruggiero G , et al.   Effect of non-steroidal anti-inflammatory drugs on colon carcinoma Caco-2 cell responsiveness to topoisomerase inhibitor drugs . Br J Cancer . 2002;86:1501–1509
  45. Rosenberg L , Palmer JR , Zauber AG , et al.   A hypothesis (Nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer) . J Natl Cancer Inst . 1991;83:355–358
  46. Suh O , Mettlin C , Petrelli NJ . Aspirin use, cancer, and polyps of the large bowel . Cancer . 1993;72:1171–1177
  47. Greenberg ER , Baron JA , Freeman DH , et al.   Reduced risk of large-bowel adenomas among aspirin users . J Natl Cancer Inst . 1993;85:912–916
  48. Muscat JE , Stellman SD , Wynder EL . Nonsteroidal anti-inflammatory drugs and colorectal cancer . Cancer . 1994;74:1847–1854
  49. Smalley W , Ray WA , Daugherty J , et al.   Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer (A population-based study) . Arch Intern Med . 1999;159:161–166
  50. García-Rodríguez LA , Huerta-Alvarez C . Reduced incidence of colorectal adenoma among long-term users of nonsteroidal anti-inflammatory drugs (A pooled analysis of published studies and a new population-based study) . Epidemiology . 2000;11:376–381
  51. García-Rodríguez LA , Huerta-Alvarez C . Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs . Epidemiology . 2001;12:88–93
  52. Baron JA , Cole BF , Sandler RS , et al.   A randomized trial of aspirin to prevent colorectal adenomas . N Engl J Med . 2003;348:891–899
  53. Rahme E , Barkun AN , Toubouti Y , et al.   The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence . Gastroenterology . 2003;125:404–412
  54. Schreinemachers DM , Everson RB . Aspirin use and lung, colon, and breast cancer incidence in a prospective study . Epidemiology . 1994;5:138–146
  55. Giovannucci E , Egan KM , Hunter DJ , et al.   Aspirin and the risk of colorectal cancer in women . N Engl J Med . 1995;333:609–614
  56. Giovannucci E , Rimm EB , Stampfer MJ , et al.   Aspirin use and the risk for colorectal cancer and adenoma in male health professionals . Ann Intern Med . 1994;121:241–246
  57. Thun MJ , Nomboodiri MM , Heath CW . Aspirin use and reduced risk of fatal colon cancer . N Engl J Med . 1991;325:1593–1596
  58. Sandler RS , Halabi S , Baron JA , et al.   A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer . N Engl J Med . 2003;348:883–890
  59. Gann PH , Manson JE , Glynn RJ , et al.   Low-dose aspirin and incidence of colorectal tumors in a randomized trial . J Natl Cancer Inst . 1993;85:1220–1224
  60. Stürmer T , Glynn RJ , Lee I-M , et al.   Aspirin use and colorectal cancer (Post-trial follow-up data from the Physicians’ Health Study) . Ann Intern Med . 1998;128:713–720
  61. Waddell WR , Loughry RW . Sulindac for polyposis of the colon . J Surg Oncol . 1983;24:83–87
  62. Waddell WR , Ganser GF , Cerise EJ , et al.   Sulindac for polyposis of the colon . Am J Surg . 1989;157:175–179
  63. Giardiello FM , Hamilton SR , Krush AJ , et al.   Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis . N Engl J Med . 1993;328:1313–1316
  64. Steinbach G , Lynch PM , Phillips RKS , et al.   The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis . N Engl J Med . 2000;342:1946–1952
  65. Phillips RKS , Wallace MH , Lynch PM , et al.   A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis . Gut . 2002;50:857–860
  66. Seow-Choen F , Vijayan V , Keng V , et al.   Prospective randomized study of sulindac versus calcium and calciferol for upper gastrointestinal polyps in familial adenomatous polyposis . Br J Surg . 1996;83:1763–1766
  67. Becerra CR , Frenkel EP , Ashfaq R , et al.   Increased toxicity and lack of efficacy of rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer (A phase II study) . Int J Cancer . 2003;105:868–872
  68. Blanke CD , Benson AB , Dragovich T , et al.   A phase II trial of celecoxib, irinotecan, 5-fluorouracil, and leucovorin in patients with unresectable or metastatic colorectal cancer . Proc Am Soc Clin Oncol . 2002;21:505; (abstr)
  69. Pan C , Loehrer P , Juliar B , et al.   A phase II trial of irinotecan, 5-fluorouracil, leucovorin (IFL), celecoxib and glutamine as first line therapy for advanced colorectal cancer (A Hoosier Oncology Group study) . Proc Am Soc Clin Oncol . 2003;22:1347; (abstr)
  70. Lin EH , Morris J , Chau NK , et al.   Celecoxib attenuated capecitabine induced hand-and-foot syndrome and diarrhea and improved time to tumor progression in metastatic colorectal cancer . Proc Am Soc Clin Oncol . 2002;21:2364; (abstr)
  71. www.EORTC.be/protoc/listopen.asp

PII: S0093-7754(04)00464-6

doi: 10.1053/j.seminoncol.2004.09.035

Seminars in Oncology
Volume 32, Issue 1 , Pages 69-75 , February 2005

Article Tools